Lipid Disorders is an indication for drug development with over 200 pipeline drugs currently active. According to GlobalData, preregistered drugs for Lipid Disorders have a 88.24% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Lipid Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lipid Disorders overview
Abnormal levels of triglycerides and LDL in the blood. A buildup of LDLs and triglycerides can cause fatty materials to accumulate in the body’s tissues, including in the arteries leading to atherosclerosis. Increased levels of these fat are referred to as hyperlipidemia or dyslipidemia. Genetic hierarchy, lifestyle changes, obesity are common causes. Symptoms include yellowish, fatty bumps or yellow creases on the skin known as xanthoma or yellow lumps in the cornea of eyes. Diagnosed by lipid profile test. Statins are first line therapy then Cholesterol inhibitors, bile acid sequestrants and fibrates.
For a complete picture of PTSR and LoA scores for drugs in Lipid Disorders, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
